A Comprehensive Pharmacological and Clinical Review of Lumbricus rubellus Extract and its Primary Bioactive Component, Lumbrokinase

Section 1: Historical Context and Biochemical Profile

The journey of Lumbricus rubellus extract from an ancient folk remedy to a subject of modern clinical investigation represents a compelling case study in ethnopharmacology. This section details its historical roots, the scientific discovery of its key bioactive components, its complex biochemical profile, and the physicochemical properties that underpin its therapeutic potential.

1.1. Traditional Use and Modern Discovery

The medicinal use of earthworms is deeply entrenched in the history of traditional Asian medicine, with documented applications spanning centuries in Chinese, Japanese, Korean, and Vietnamese cultures.[1] Referred to as Dilong (or "Earth Dragon") in Traditional Chinese Medicine, preparations derived from earthworms have been historically prescribed for a wide array of conditions, particularly those believed to involve circulatory stasis, inflammation, and disorders of the liver and spleen.[1] This long-standing empirical use for hematological and circulatory ailments provided a crucial foundation, suggesting the presence of potent, biologically active compounds that warranted scientific exploration.[5]

The transition from traditional remedy to modern biopharmaceutical began in earnest in the late 20th century. The pivotal breakthrough occurred in 1991 when a team of Japanese researchers, led by Dr. Hisashi Mihara, successfully isolated and characterized a group of powerful fibrinolytic enzymes from the earthworm species Lumbricus rubellus.[5] Recognizing their potent ability to dissolve fibrin, the primary protein component of blood clots, they collectively named this enzyme complex "lumbrokinase" (LK), a name derived from the earthworm's genus.[5] This discovery was a landmark event, providing a specific biochemical basis for the observed therapeutic effects of traditional earthworm preparations and launching a new field of research into its potential as a modern thrombolytic agent.[4] The scientific validation of this traditional knowledge serves as a powerful example of how ancient medicinal practices can provide invaluable leads for the discovery of novel therapeutic agents, bridging the gap between historical wisdom and contemporary, evidence-based medicine.

1.2. Composition of Lumbricus rubellus Extract

The therapeutic activity of Lumbricus rubellus extract is not attributable to a single molecule but rather to a complex mixture of bioactive compounds. While the lumbrokinase enzyme complex is the most studied and therapeutically relevant component for cardiovascular applications, the whole extract contains other substances that contribute to its broader biological effects.

The Lumbrokinase Enzyme Complex

The primary active principle of the extract is lumbrokinase, a complex of several distinct proteolytic enzymes.[8] It is not a monolithic entity but a group of at least six novel serine protease isozymes that work synergistically.[6] Extensive biochemical characterization has revealed that these isozymes have molecular weights ranging from approximately 23 to 32 kDa.[7]

Studies have successfully fractionated these isozymes, such as those designated F-I-0 through F-III-2, demonstrating that they possess varying degrees of fibrinolytic and caseinolytic (protein-degrading) activity, with some fractions like F-III-1 and F-III-2 showing particularly high potency.[11] Standardized extracts developed for clinical research, such as the Indonesian-derived DLBS1033, are characterized by a specific protein profile, typically comprising eight major proteins with molecular weights below 100 kDa.[6] It is important to note that the precise composition and activity of the lumbrokinase complex can vary depending on the species of earthworm used (e.g., Lumbricus rubellus, Eisenia fetida, Pheretima sp.) and even the specific living environment of the source organism, which can influence the relative abundance of different isozymes.[6]

Other Bioactive Compounds

Beyond the well-characterized lumbrokinase complex, the whole extract of Lumbricus rubellus is a rich source of other biologically active molecules. One of the most significant is Lumbricin-1, a potent antimicrobial peptide (AMP).[2] This peptide is a key component of the earthworm's innate immune system, providing a natural defense against pathogenic microbes. In vitro studies have confirmed that Lumbricin-1 is responsible for the extract's observed broad-spectrum antibacterial properties, demonstrating inhibitory activity against clinically relevant pathogens such as Escherichia coli and Salmonella typhi.[2]

Additionally, the coelomic fluid of the earthworm contains a diverse array of over 40 proteins involved in various biological activities, including cytolytic, hemolytic, and mitogenic functions.[14] The extract is also a source of essential and non-essential amino acids, minerals like phosphorus and calcium, and potentially phenolic compounds that may confer antioxidant properties.[14] This complex biochemical milieu suggests that while lumbrokinase is the primary driver of the extract's effects on hemostasis, other components may contribute to its anti-inflammatory, antimicrobial, and general health-promoting effects observed in traditional use and preliminary modern research.

1.3. Production, Physicochemical Properties, and Stability

The production of modern, clinical-grade Lumbricus rubellus extract has evolved from simple traditional preparations to sophisticated, standardized manufacturing processes. These processes typically begin with farm-raised earthworms, which are subjected to aqueous extraction followed by continuous centrifugation to separate the active protein fractions.[1] The resulting supernatant is then concentrated and converted into a fine, light yellow to brown powder, often using techniques like fluid bed drying.[1] To ensure microbial safety and prevent contamination with bacterial proteases that could interfere with activity assays, the final product may be sterilized, for instance, by gamma irradiation, as is the case with the standardized extract DLBS1033.[6]

In recent years, advances in biotechnology have opened new avenues for production. The use of recombinant gene technology to manufacture specific lumbrokinase isozymes is being explored.[4] This approach offers the potential for producing highly purified, single-enzyme preparations in much larger volumes, which could lead to greater standardization and a more consistent therapeutic product.

A defining and critically important feature of the lumbrokinase enzyme complex is its exceptional physicochemical stability. This property is not merely a biochemical detail but is the fundamental enabler of its primary clinical advantage over other thrombolytic agents: oral administration. Conventional thrombolytic drugs like tissue plasminogen activator (t-PA), urokinase, and streptokinase are proteins that are rapidly denatured by the harsh acidic environment of the stomach and must be administered intravenously in a hospital setting.[10] In stark contrast, lumbrokinase demonstrates remarkable resilience. It retains its enzymatic activity across an unusually broad pH range, from approximately pH 4 up to pH 12, allowing it to survive gastric transit.[6] Furthermore, it exhibits significant thermal stability, with an optimal activity temperature around 50°C and resistance to denaturation at higher temperatures compared to its counterparts.[6] This inherent stability is the key that unlocks its potential for oral use, enabling convenient, long-term administration in outpatient settings for chronic disease management and secondary prevention—a therapeutic niche that is entirely inaccessible to IV-only thrombolytics designed for acute emergencies.

Section 2: Pharmacodynamics and Multifaceted Mechanisms of Action

The pharmacodynamic profile of lumbrokinase is complex and multifaceted, extending far beyond a simple "clot-busting" effect. It interacts with the human hemostatic system at multiple levels, demonstrating potent fibrinolytic, antithrombotic, and anti-platelet activities. Furthermore, emerging evidence reveals novel mechanisms involving anti-inflammatory and direct cellular protection pathways, which may explain its broad therapeutic benefits in cardiovascular and cerebrovascular diseases.

2.1. Foundational Context: The Coagulation and Fibrinolytic Systems

To fully comprehend the mechanisms of lumbrokinase, it is essential to first understand the physiological systems it modulates. Hemostasis is a delicate balance between pro-coagulant (clot-forming) and anticoagulant/fibrinolytic (clot-dissolving) forces.

The coagulation cascade is a series of enzymatic reactions initiated in response to vascular injury. This process culminates in the enzyme thrombin converting the soluble plasma glycoprotein fibrinogen into an insoluble polymer called fibrin. This fibrin polymerizes to form a tough, fibrous mesh that traps platelets and red blood cells, creating a stable blood clot to prevent hemorrhage.[23]

Conversely, the fibrinolytic system is the body's endogenous mechanism for degrading clots once they are no longer needed, thereby restoring blood flow. The central enzyme in this system is plasmin, which is a potent protease that cleaves the fibrin mesh into smaller, soluble fragments. Plasmin circulates in an inactive proenzyme form called plasminogen. The conversion of plasminogen to active plasmin is primarily catalyzed by tissue plasminogen activator (t-PA), which is released from endothelial cells.[8] The activity of this system is tightly regulated by inhibitors, most notably plasminogen activator inhibitor-1 (PAI-1), which binds to and inactivates t-PA.[24] A hypercoagulable state, where the blood is excessively prone to clotting, can arise from various pathologies, including chronic inflammation (which increases clotting factor production) or impaired fibrinolysis (often due to elevated PAI-1 levels), tipping the hemostatic balance towards thrombosis.[24]

2.2. Primary Fibrinolytic and Thrombolytic Mechanisms

Lumbrokinase exerts its powerful thrombolytic (clot-dissolving) effects through a sophisticated, dual-pronged mechanism that both mimics and enhances the body's natural fibrinolytic processes.[18]

1. Direct Fibrinolysis: Lumbrokinase functions as a direct-acting, plasmin-like enzyme. It possesses the intrinsic proteolytic capability to directly cleave and degrade the fibrin mesh of an existing thrombus.[4] Unlike many conventional thrombolytics that rely solely on activating the body's own machinery, lumbrokinase can act upon the clot structure itself. This direct action also extends to fibrinogen, the precursor to fibrin, which contributes to its antithrombotic effects by reducing the available substrate for clot formation.[4]
2. Indirect Fibrinolysis: In addition to its direct action, lumbrokinase also serves as a potent plasminogen activator. It promotes the conversion of the body's endogenous plasminogen into active plasmin, thereby amplifying the natural clot-dissolving cascade.[5] This indirect mechanism is multifaceted; studies indicate that lumbrokinase not only directly facilitates this conversion but also increases the activity of the body's own t-PA and simultaneously inhibits the primary fibrinolysis inhibitor, PAI-1.[12] By both stimulating the activators and inhibiting the inhibitors of the fibrinolytic system, lumbrokinase creates a robust pro-fibrinolytic environment.

The most profound and clinically significant pharmacodynamic property of lumbrokinase is its high specificity for fibrin. This characteristic fundamentally distinguishes it from conventional thrombolytic agents and is the cornerstone of its favorable safety profile. Multiple studies emphasize that lumbrokinase is primarily active only in the presence of a fibrin clot.[5] This stands in stark contrast to non-specific agents like streptokinase and urokinase, which can induce a state of systemic fibrinolysis by indiscriminately degrading not only fibrin but also essential circulating proteins like fibrinogen and plasminogen throughout the bloodstream.[5] This systemic degradation leads to a dangerous state of hypocoagulability, creating a high risk of spontaneous and severe hemorrhage. By selectively targeting the pathological structure—the fibrin clot—while largely sparing the components of normal hemostasis, lumbrokinase effectively decouples its therapeutic efficacy from this high bleeding risk. This "smart" mechanism provides a direct biochemical explanation for the consistent safety findings in clinical trials, where significant increases in major bleeding events are notably absent.[12] This makes lumbrokinase an exceptionally attractive agent for therapeutic scenarios requiring a sustained but gentle fibrinolytic effect without the high-stakes risk of systemic thrombolysis.

2.3. Antithrombotic and Anti-platelet Aggregation Effects

Beyond its ability to dissolve existing clots, lumbrokinase possesses significant antithrombotic properties that actively prevent the formation of new thrombi. A key component of this activity is its marked effect on platelet function. Platelet aggregation, the process by which platelets become "sticky" and adhere to one another and to the site of vascular injury, is the initial step in thrombus formation. Lumbrokinase has been shown to be a potent inhibitor of platelet aggregation.[4]

Mechanistic studies have begun to elucidate how it achieves this effect. Evidence suggests that lumbrokinase may inhibit platelet activation by reducing the intracellular release of calcium ions ($Ca^{2+}$), a critical signaling event for aggregation.[12] Furthermore, it has been shown to downregulate the expression of intercellular adhesion molecule-1 (ICAM-1), a protein on the surface of endothelial cells and leukocytes that facilitates cell-to-cell adhesion, including platelet adhesion.[12] By interfering with these crucial early steps, lumbrokinase effectively reduces the propensity for new clots to form.

These anti-platelet effects, combined with its ability to degrade fibrinogen and lower overall blood viscosity, contribute to a comprehensive antithrombotic profile.[5] The net result is a prolongation of blood clotting time and a circulatory environment that is less conducive to pathological thrombosis.

2.4. Anti-inflammatory and Cardioprotective Mechanisms

While lumbrokinase was initially characterized by its effects on hemostasis, a growing body of research reveals that its therapeutic benefits are also mediated by potent anti-inflammatory and direct tissue-protective mechanisms. This represents a significant evolution in the understanding of its pharmacodynamics, suggesting it is not merely a "plumbing" drug that clears clots, but a bioactive molecule that actively protects cells from ischemic and inflammatory damage.

Chronic inflammation is a well-established driver of cardiovascular diseases, particularly atherosclerosis, where inflammatory processes contribute to the formation and instability of arterial plaques.[4] Lumbrokinase has demonstrated anti-inflammatory properties, which may contribute to its benefits in conditions like coronary artery disease and stroke by modulating this underlying pathology.[8]

More recent and striking evidence has emerged from preclinical models of myocardial ischemia-reperfusion (I-R) injury, a condition that mimics the damage caused by a heart attack and subsequent restoration of blood flow. These studies have uncovered a novel and profound cardioprotective signaling pathway activated by lumbrokinase. Post-ischemic treatment with lumbrokinase was found to significantly upregulate the expression and activity of Silent Information Regulator 1 (Sirt1), a crucial protein involved in cellular stress resistance, metabolism, and longevity.[7]

The activation of this Sirt1 signaling pathway triggers a cascade of downstream cellular defense mechanisms that protect the heart muscle from I-R-induced damage:

• Reduction of Oxidative Stress: Sirt1 deacetylates and modulates the activity of the Forkhead Box O1 (FoxO1) transcription factor, a key regulator of cellular responses to oxidative stress. This action helps to mitigate the damaging effects of reactive oxygen species generated during reperfusion.[7]
• Anti-apoptotic Effect: Lumbrokinase treatment was shown to significantly decrease the expression of Cleaved-Caspase-3, a primary executioner enzyme in the apoptotic (programmed cell death) pathway. By inhibiting apoptosis, lumbrokinase helps preserve viable heart muscle cells that would otherwise die following an ischemic event.[7]
• Enhancement of Autophagy: Sirt1 activation also promotes autophagy, the cell's "housekeeping" process for clearing out damaged proteins and organelles. Enhanced autophagy following I-R injury helps cells recover and maintain function.[7]

This discovery of the Sirt1 pathway fundamentally broadens the therapeutic paradigm for lumbrokinase. It suggests that its clinical benefits in conditions like ischemic stroke and stable angina may arise not only from improved blood flow but also from direct neuroprotective and cardioprotective effects at the cellular level. This could explain the degree of efficacy observed in clinical trials, which may be greater than what would be expected from its fibrinolytic action alone, and it opens exciting new avenues for research into its potential for treating a wider range of ischemic and neurodegenerative diseases.

Section 3: Clinical Evidence in Cerebrovascular and Cardiovascular Diseases

The clinical utility of lumbrokinase has been most extensively investigated in the context of cerebrovascular and cardiovascular diseases, with the strongest body of evidence centered on its use in acute ischemic stroke. This section critically evaluates the human clinical trial data for its primary indications, focusing on study design, dosage, and key outcomes.

3.1. Ischemic Stroke

The use of lumbrokinase as an adjunctive therapy for acute ischemic stroke (AIS) is supported by a substantial volume of clinical research, primarily from Asia. This evidence base includes numerous randomized controlled trials (RCTs) and a recent, large-scale meta-analysis that synthesizes their findings.

Meta-Analysis of Randomized Controlled Trials (RCTs)

The most robust and comprehensive evidence to date comes from a systematic review and meta-analysis published in 2024, which aggregated data from 35 separate RCTs conducted between 2010 and 2024.[22] This analysis compared the efficacy and safety of lumbrokinase administered as an adjunct to standard supportive care versus standard supportive care alone in patients with AIS.

The primary efficacy outcomes demonstrated statistically significant and clinically meaningful benefits for the lumbrokinase group:

• Functional Independence: Patients receiving lumbrokinase showed significantly greater improvement in their ability to perform activities of daily living, as measured by the Barthel Index (BI). The analysis found a mean difference (MD) of 15.17 in favor of lumbrokinase, a substantial effect on this 100-point scale.[22]
• Neurological Deficit: The severity of neurological impairment was significantly reduced in the lumbrokinase group, as measured by the National Institutes of Health Stroke Scale (NIHSS). The analysis revealed a mean difference of -2.01, indicating a clear reduction in stroke severity.[22]

Crucially, these therapeutic gains were achieved with an excellent safety profile. The meta-analysis found no significant increase in adverse events, including gastrointestinal discomfort or, most importantly, gastrointestinal bleeding, when lumbrokinase was added to standard care.[22] Furthermore, the addition of lumbrokinase led to favorable changes in key laboratory biomarkers, providing objective in-vivo confirmation of its mechanisms of action. These included an improvement in the activated partial thromboplastin time (aPTT), a significant reduction in platelet aggregation rate, and a decrease in D-dimer levels, a marker of clot breakdown.[28]

While the collective data from this meta-analysis presents a strong and consistent signal of efficacy, it is important to contextualize these findings. The authors of the analysis themselves introduce a critical note of caution, stating that "limited evidence warrants cautious use and further high-quality trials".[22] This is because the evidence base, while large, includes many older and smaller RCTs, and some of the larger, more recent trials have methodological limitations, such as open-label designs.[26] This creates a potential evidence gap for Western regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), which typically require large, multi-center, double-blind, placebo-controlled trials. Therefore, while the existing evidence is highly promising, it may be considered preliminary by some regulatory standards, highlighting the need for future trials that adhere to the most rigorous methodological criteria.

Individual RCTs - The DLBS1033 Studies

Providing a more granular view, a large, well-documented RCT conducted in Indonesia evaluated the standardized Lumbricus rubellus extract DLBS1033 in 180 patients with first-time AIS.[26] This study exemplifies the adjunctive role of lumbrokinase, as it was administered in addition to established standard-of-care treatments.

• Study Design: This was a randomized, controlled, open-label trial. Patients with mild to moderate stroke (NIHSS < 14) and an onset of less than 24 hours were randomized into two groups. The control group received standard therapy (aspirin 100 mg/day, atorvastatin 20 mg/day, and vitamin B12). The experimental group received the same standard therapy plus DLBS1033 at a dose of 490 mg three times daily.[26]
• Outcomes: The functional outcomes were measured at baseline, hospital discharge, and at a 30-day follow-up. The results clearly favored the DLBS1033 group:
• NIHSS Score Improvement: The reduction in neurological deficit was significantly greater in the experimental group at both hospital discharge (-5.57 vs. -3.64; $p < 0.001$) and at day 30 (-6.62 vs. -5.14; $p = 0.001$).[32]
• Barthel Index Improvement: The improvement in functional independence was also significantly better in the DLBS1033 group at both discharge (10.69 vs. 6.64; $p < 0.001$) and at day 30 (10.9 vs. 8.56; $p = 0.003$).[32]
• Modified Rankin Scale (mRS): The distribution of mRS scores, a global measure of disability, was more favorable in the experimental group. At day 30, 86.7% of patients in the lumbrokinase group achieved a favorable outcome (mRS < 2) compared to 80% in the control group.[32]
• Safety: Consistent with the meta-analysis, there were no clinically significant adverse events attributed to the study product, reinforcing its safety when added to standard antiplatelet and statin therapy.[32]

A recurring and important theme across all these clinical trials is the positioning of lumbrokinase as an adjunctive or add-on therapy, rather than a replacement for the existing standard of care. This strategy is both mechanistically and clinically sound. Lumbrokinase's unique fibrinolytic and anti-platelet mechanisms are complementary to, not redundant with, the actions of standard antiplatelet agents like aspirin or lipid-lowering statins. This approach leverages its unique benefits to enhance the overall therapeutic effect, fitting seamlessly into existing treatment paradigms and representing a lower-risk clinical development strategy. The future success of lumbrokinase likely lies in its role as a synergistic component of a multi-modal treatment regimen for cerebrovascular disease.

Table 1: Summary of Key Clinical Trials for Lumbrokinase in Ischemic Stroke

Study / Analysis	Study Design	Patient Population	N	Dosage / Intervention	Duration	Key Efficacy Outcomes	Key Safety Finding	Source(s)
Meta-Analysis (2024)	Meta-analysis of 35 RCTs	Acute Ischemic Stroke (AIS)	-	Lumbrokinase + Supportive Care vs. Supportive Care Alone	Varied	Barthel Index: $MD = 15.17$ ($p<0.00001$) NIHSS Score: $MD = -2.01$ ($p<0.00001$)	No significant increase in adverse events, including GI bleeding.	22
DLBS1033 Trial	Randomized, Controlled, Open-Label	First-time AIS, onset <24h, NIHSS <14	180	Experimental: Standard Care + DLBS1033 490 mg TID Control: Standard Care Alone	30 Days	NIHSS Improvement (Day 30): -6.62 (LK) vs. -5.14 (Control); $p=0.001$ BI Improvement (Day 30): 10.9 (LK) vs. 8.56 (Control); $p=0.003$ Favorable mRS (<2) at Day 30: 86.7% (LK) vs. 80% (Control)	No clinically significant adverse events related to the study product.	26

3.2. Stable Angina Pectoris and Coronary Artery Disease (CAD)

While the evidence base is less extensive than for stroke, preliminary clinical studies suggest that lumbrokinase may also be beneficial for patients with chronic coronary artery disease, particularly stable angina pectoris. Its mechanisms of action—improving blood flow, reducing blood viscosity, and inhibiting platelet aggregation—are highly relevant to the pathophysiology of CAD.

Pilot Study on Myocardial Perfusion

The most significant clinical evidence in this area comes from a pilot study conducted in Indonesia, which objectively assessed the effects of oral lumbrokinase on myocardial perfusion in patients with stable angina.[16]

• Design and Dosage: This was a single-armed cohort study involving 10 patients with confirmed CAD and symptomatic stable angina. The patients received oral lumbrokinase for 30 consecutive days in addition to their existing standard medical therapy. The dosage consisted of 250 mg capsules, with each capsule providing an activity of 300,000 units.[29]
• Objective Outcomes: Myocardial perfusion was quantitatively assessed using technetium-99m sestamibi myocardial perfusion imaging (MPI) before and after the 30-day treatment period. The results showed a remarkable improvement in blood flow to the heart muscle:
• The mean Summed Stress Score (SSS), which quantifies the extent and severity of perfusion defects during stress, decreased from 15.1 to 9.2, representing a mean reduction of 39%.[29]
• The mean Summed Difference Score (SDS), which reflects the amount of reversible ischemia, decreased from 12 to 7.6, a mean reduction of 37%.[29]
• Subjective and Safety Outcomes: In addition to the objective imaging data, 6 out of the 10 patients (60%) reported an amelioration of their anginal symptoms. Importantly, and consistent with other clinical trials, no adverse reactions, including major or minor bleeding events, were observed during the study.[29]

Although this was a small, unblinded pilot study, its findings are significant as it was the first to use objective MPI to demonstrate that oral lumbrokinase can improve myocardial perfusion in patients with chronic stable angina. In broader clinical practice, particularly in China, lumbrokinase is widely used for the treatment of coronary heart disease and angina pectoris.[5] The collective evidence suggests it may improve outcomes in CAD patients by enhancing blood flow, reducing the frequency of arrhythmia, and improving overall cardiovascular blood markers.[4]

3.3. Deep Vein Thrombosis (DVT) and Venous Health

The mechanistic rationale for using lumbrokinase in the management of venous thromboembolic disease, including deep vein thrombosis (DVT), is compelling. Its core properties—dissolving fibrin, reducing blood viscosity, and preventing platelet aggregation—directly counteract the pathological processes that lead to the formation of thrombi in the deep veins.[35]

While large-scale, placebo-controlled RCTs for DVT are not as prevalent in the available literature as those for stroke, lumbrokinase is used clinically for this indication in China.[5] Smaller studies and clinical experience have reported positive effects on relevant biomarkers, showing decreases in D-dimer and fibrinogen levels, which are indicative of reduced clot burden and formation, alongside objective improvements in venous blood flow.[35]

One study provided preliminary evidence for a potential synergistic role with conventional anticoagulants. It found that a combination therapy of lumbrokinase plus warfarin resulted in a trend toward better thrombus resolution in DVT patients compared to warfarin monotherapy.[36] Although this difference did not reach statistical significance, it suggests that lumbrokinase could serve as a valuable adjunctive therapy to enhance the efficacy of standard anticoagulation regimens. Given the moderate level of existing scientific evidence, there is a clear need for larger, more rigorously designed clinical trials to definitively establish the efficacy and safety of lumbrokinase for the prevention and treatment of DVT and chronic venous insufficiency.[35]

Section 4: Therapeutic Potential in Emerging and Other Conditions

The therapeutic applications of Lumbricus rubellus extract and its primary component, lumbrokinase, are expanding beyond the traditional realm of cardiovascular and cerebrovascular diseases. Driven by new hypotheses about the pathophysiology of chronic illnesses and a deeper understanding of its multifaceted mechanisms, lumbrokinase is now being investigated for a range of emerging and novel conditions.

4.1. Post-Viral Syndromes (Long COVID, ME/CFS, Long Lyme)

Perhaps the most significant and novel therapeutic pivot for lumbrokinase is its investigation as a potential treatment for chronic, post-infectious syndromes like Long COVID, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and Post-treatment Lyme Disease Syndrome. This emerging application moves the focus from treating acute, macro-vascular thrombosis to addressing a hypothesized underlying pathology of chronic, micro-vascular thrombosis and persistent inflammation.

Hypothesis and Rationale

The central hypothesis driving this research is that a key driver of the debilitating symptoms in these conditions—such as profound fatigue, post-exertional malaise, and cognitive dysfunction ("brain fog")—is the formation of persistent, anomalous fibrin/amyloid microclots in the circulatory system.[37] These microclots are theorized to be resistant to the body's normal fibrinolytic processes and are believed to occlude capillaries, thereby impeding blood flow and preventing adequate oxygenation of tissues throughout the body. This state of tissue hypoxia, combined with platelet hyperactivation and associated inflammatory signaling, is thought to contribute significantly to the symptom burden.[37] Lumbrokinase, with its well-established fibrin-dissolving properties, oral bioavailability, and excellent safety profile, is an ideal therapeutic candidate to test this microclot hypothesis and potentially offer a first-in-class treatment for these major unmet medical needs.

Ongoing Clinical Trial (NCT06511050)

This hypothesis is currently being tested in a formal clinical trial sponsored by the Icahn School of Medicine at Mount Sinai.[38]

• Design: The study (NCT06511050) is a pilot, multi-arm, open-label clinical trial designed to investigate the feasibility, safety, and preliminary efficacy of lumbrokinase (using the Boluoke® brand) in three distinct patient cohorts: Long COVID, ME/CFS, and Post-treatment Lyme Disease Syndrome.[38]
• Dosage: Participants in each arm of the trial are administered Boluoke® brand lumbrokinase capsules daily for a period of six weeks.[38]
• Endpoints: The primary goals of the trial are to establish whether daily use of lumbrokinase is well-tolerated in these patient populations and to determine if the treatment is associated with symptom improvement. A key secondary endpoint involves measuring the levels of fibrin/amyloid microclots in the blood before and after treatment to see if lumbrokinase can disrupt their formation or clear existing deposits.[37]

If this trial yields positive results, it could represent a monumental shift in the treatment landscape for millions of individuals suffering from these chronic, debilitating conditions. A successful outcome would not only validate the microclot theory as a key pathological mechanism but would also position lumbrokinase as a foundational therapy, marking the most significant expansion of its clinical utility to date.

4.2. Antimicrobial and Anti-Diarrheal Applications

Separate from its effects on hemostasis, Lumbricus rubellus extract has demonstrated notable antimicrobial properties in vitro. This activity is primarily attributed to the presence of Lumbricin-1, a potent antimicrobial peptide found within the earthworm's coelomic fluid.[2]

Studies have shown that the extract can inhibit the growth of a broad spectrum of pathogenic bacteria. Specifically, it has demonstrated efficacy against Escherichia coli, a common cause of enteropathogenic diarrhea, and Salmonella typhi, the bacterium responsible for typhoid fever.[2] This suggests a potential, albeit less explored, therapeutic role for the extract as an anti-diarrheal or adjunctive antibacterial agent. The efficacy may depend on the extraction method used, as different solvents may yield varying concentrations of Lumbricin-1.[18] While this area of research is still in its early stages and lacks human clinical trial data, it highlights the diverse bioactive potential of the whole earthworm extract beyond the lumbrokinase enzymes.

4.3. Other Investigated Areas

The unique combination of fibrinolytic, anti-inflammatory, and tissue-protective properties of lumbrokinase has led to its investigation in several other clinical contexts.

• Diabetic Nephropathy: Preliminary research has suggested that lumbrokinase may offer benefits for patients with diabetic nephropathy. The proposed mechanism involves improving kidney function, which often declines in this condition partly due to toxic buildup and impaired microcirculation.[4] By potentially improving blood flow and reducing inflammation within the renal microvasculature, lumbrokinase may help preserve kidney function.
• Intra-Abdominal Adhesions: Preclinical studies have yielded promising results for the use of lumbrokinase in preventing the formation of post-surgical intra-abdominal adhesions. These adhesions are essentially internal scar tissue, largely composed of fibrin deposits, that can cause chronic pain, bowel obstruction, and infertility. Studies have shown that lumbrokinase can significantly decrease the severity and area of adhesion formation by augmenting the fibrinolytic activity of the injured peritoneum and by inhibiting the migration and adhesive activities of fibroblasts, the cells responsible for producing scar tissue.[31]
• General Anti-inflammatory and Antioxidant Effects: The extract is also being explored for its more general health benefits. Its anti-inflammatory and potential antioxidant properties may be relevant to a variety of conditions characterized by chronic inflammation, such as adrenal fatigue.[4]

These emerging areas of research underscore the versatility of Lumbricus rubellus extract as a therapeutic agent. While further investigation, particularly well-designed clinical trials, is required to validate these potential applications, they highlight the broad range of pathologies where its unique mechanisms of action could prove beneficial.

Section 5: Pharmacokinetics, Administration, and Standardization

The practical application of lumbrokinase as a therapeutic agent depends on its pharmacokinetic profile, appropriate methods of administration, and, most critically, the ability to standardize its potency. This section addresses how the enzyme is absorbed and dosed, and examines the significant challenges related to ensuring consistent and reliable enzymatic activity.

5.1. Oral Bioavailability and Absorption

A fundamental question for any orally administered protein-based therapeutic is whether it can survive the digestive process and be absorbed into the systemic circulation in a biologically active form. For lumbrokinase, a substantial body of evidence indicates that this is indeed possible. Despite being a complex of protein enzymes, a portion of the lumbrokinase complex is capable of being transported across the intestinal epithelium and into the bloodstream while retaining its enzymatic function.[6]

This crucial pharmacokinetic property has been confirmed in animal models using immunological techniques. Studies have successfully detected the presence of intact, immunoreactive lumbrokinase enzyme in the serum or plasma of rats following oral administration or intraperitoneal injection.[12] These findings provide direct evidence that the enzyme is not fully degraded in the gastrointestinal tract and can achieve systemic bioavailability. This absorption is the essential prerequisite for its observed systemic effects on fibrinolysis, platelet aggregation, and blood viscosity.

5.2. Dosage Forms and Recommended Dosing

Reflecting its oral bioavailability, lumbrokinase is almost exclusively administered orally, most commonly in the form of capsules or tablets.[8] To further protect the enzymes from potential degradation by gastric acid and ensure they reach the small intestine for optimal absorption, modern formulations frequently utilize delayed-release or acid-resistant (enteric-coated) capsules.[39] It is generally recommended to take lumbrokinase on an empty stomach (e.g., 30 minutes before or two hours after a meal) to maximize absorption and efficacy.[8]

The recommended dosage of lumbrokinase varies considerably depending on the intended use (e.g., dietary supplement vs. therapeutic agent) and the specific product formulation.

• As a Dietary Supplement: Dosing is often described in milligrams of extract. Common dosages range from 20 to 60 milligrams per day, typically divided into two or three doses.[8]
• In Clinical Trials: For therapeutic applications such as acute ischemic stroke, significantly higher doses are employed. For example, the pivotal trials for the standardized extract DLBS1033 used a dose of 490 mg three times daily.[26]
• By Activity Units: A more precise method of dosing is by enzymatic activity. Commercial supplements often state their potency in International Units (IU), with typical servings providing between 600,000 IU and 880,000 IU.[9] For severe conditions, practitioners may recommend higher doses, such as two capsules three times daily.[3]

5.3. The Challenge of Potency and Standardization

A major scientific and regulatory challenge that currently hinders the widespread clinical adoption of lumbrokinase is the lack of a universally accepted standard for measuring its potency. For enzymatic products, the therapeutic effect is determined by the enzyme's activity, not simply its weight in milligrams.[24] Two products containing the same milligram amount of lumbrokinase extract can have dramatically different levels of fibrinolytic activity due to variations in purity, isozyme composition, and manufacturing processes.

This issue is compounded by the use of several different, and critically, non-interchangeable, units of activity in the marketplace and in scientific literature:

• International Units (IU): A globally recognized and standardized measure of enzymatic activity, where one IU corresponds to a defined quantity of substrate converted per unit of time under specified conditions.[24]
• Fibrinolytic Units (FU): A unit commonly used to measure the activity of nattokinase and other fibrinolytic enzymes. It quantifies the ability of the enzyme to degrade fibrin in a laboratory setting, but the specific methodology of the assay can vary between laboratories, limiting direct comparability.[24]
• Lumbrokinase Units (LKU): A unit developed specifically for lumbrokinase. However, there is no international standard for the LKU. It is typically defined by individual manufacturers or laboratories using their own proprietary reference standards, making it impossible to reliably compare the potency of products from different suppliers based on their LKU values.[24]

This "standardization gap" represents a significant barrier to the advancement of lumbrokinase from a dietary supplement to a conventional pharmaceutical. A clinician cannot prescribe "lumbrokinase" with the same confidence and precision as they can prescribe "atorvastatin 20 mg" because the actual biological activity delivered to the patient can vary unpredictably between different products. This inconsistency makes it extremely difficult to replicate clinical trial results, establish clear dose-response relationships, and develop evidence-based clinical practice guidelines. For lumbrokinase to achieve its full therapeutic potential and gain acceptance from global regulatory bodies, the development of a standardized, universally accepted unit of fibrinolytic activity, calibrated against a stable international reference standard, is an essential and urgent priority.

Section 6: Safety, Tolerability, and Drug Interactions

A comprehensive assessment of the safety profile of any therapeutic agent is paramount, particularly for one that modulates the delicate balance of the hemostatic system. Across a wide range of preclinical and clinical studies, lumbrokinase has consistently demonstrated a favorable safety and tolerability profile, which is one of its most distinguishing and clinically valuable attributes.

6.1. Documented Side Effects and Adverse Events

Lumbrokinase is generally reported to be very well-tolerated by most individuals.[8] When side effects do occur, they are typically mild and transient.

• Common Side Effects: The most frequently reported adverse effects are gastrointestinal in nature, including mild nausea or diarrhea.[8]
• Rare Adverse Events: More serious reactions are uncommon but can include allergic or hypersensitivity reactions in individuals with a pre-existing allergy to earthworms or other components of the supplement formulation. These reactions may manifest as a skin rash or itching.[8]

Importantly, extensive toxicological experiments in animal models and data from numerous human clinical trials have found no evidence of significant organ toxicity. Studies have shown no negative effects on the nervous, cardiovascular, or respiratory systems, nor any adverse impact on liver or kidney function.[5] Furthermore, lumbrokinase does not appear to affect metabolic parameters such as blood glucose or lipid levels.[12]

The most remarkable aspect of its safety profile is the consistent observation of potent fibrinolytic activity without a correspondingly high risk of spontaneous hemorrhage. This clinical paradox is a direct consequence of its fibrin-specific mechanism of action. As previously discussed, lumbrokinase is primarily active in the presence of a fibrin clot, allowing it to target pathological thrombi while largely sparing the components of the normal, circulating coagulation system.[5] This is supported by laboratory findings showing that lumbrokinase does not significantly alter standard coagulation tests like prothrombin time (PT), activated partial thromboplastin time (aPTT), or the International Normalized Ratio (INR).[3] This unique safety profile distinguishes it from virtually all other thrombolytic agents and is what makes its consideration for long-term oral use feasible.

6.2. Contraindications and High-Risk Populations

Despite its favorable safety profile, there are specific populations and clinical situations in which the use of lumbrokinase is contraindicated due to an increased risk of bleeding.

• Bleeding Disorders: Individuals with inherited or acquired bleeding disorders, such as hemophilia, should not use lumbrokinase.[4]
• Allergy: A known allergy or hypersensitivity to earthworms or any other ingredient in the product is an absolute contraindication.[3]
• Peri-operative Period: To minimize the risk of excessive surgical bleeding, it is recommended that lumbrokinase be discontinued before any scheduled surgery (typically one week prior) and not resumed until well into the post-operative period (typically two weeks after), pending approval from the supervising physician.[4]
• Active Bleeding: Lumbrokinase is contraindicated in any condition associated with active or recent bleeding, such as active peptic ulcer disease, or in patients with a high-risk aneurysm.[3]
• Recent Trauma or Puncture: Use should be avoided following recent major trauma, lumbar puncture, or arterial puncture.[3]

6.3. Clinically Significant Drug Interactions

The primary concern for drug-drug interactions with lumbrokinase involves the potential for additive or synergistic effects with other medications that influence hemostasis. Co-administration can theoretically increase the overall risk of bleeding complications, and therefore requires caution and medical supervision.[8]

• Anticoagulant Drugs: Concomitant use with anticoagulant medications—such as warfarin (Coumadin®), heparin, and direct oral anticoagulants (DOACs) like rivaroxaban or apixaban—should be approached with caution. While some evidence suggests lumbrokinase does not directly interfere with the clotting cascade in the same way as warfarin (i.e., it does not affect INR), the combined effect on hemostasis could increase bleeding risk. Medical supervision is essential for any patient considering this combination.[8]
• Antiplatelet Agents: Similarly, caution is advised when lumbrokinase is used alongside antiplatelet drugs like aspirin or clopidogrel (Plavix®). Since both agents inhibit platelet aggregation, their combined use could potentially lead to an enhanced antiplatelet effect and a higher risk of bleeding.[8] Although some clinical studies have shown lumbrokinase to be safe when taken with aspirin, patients should always consult their physician before combining these agents.[40]

In all cases where a patient is taking prescription anticoagulant or antiplatelet medications, the decision to add lumbrokinase to their regimen should be made in consultation with a qualified healthcare practitioner who can weigh the potential benefits against the risks and monitor the patient appropriately.

Section 7: Comparative Analysis and Global Regulatory Landscape

To fully contextualize the role of lumbrokinase in modern therapeutics, it is essential to compare it with other popular enzymatic supplements and to understand its complex and varied regulatory status across different global regions. This section provides a comparative analysis and examines the fragmented regulatory landscape that currently governs its use.

7.1. Lumbrokinase vs. Nattokinase and Serrapeptase

Lumbrokinase is often discussed alongside two other widely used proteolytic enzyme supplements: nattokinase and serrapeptase. While all three are marketed for their systemic enzymatic effects, particularly related to inflammation and circulatory health, they possess fundamental differences in their source, mechanism of action, and, most importantly, their substrate specificity.

Source

• Lumbrokinase: Derived from various species of earthworm, most commonly Lumbricus rubellus and Eisenia fetida.[1]
• Nattokinase: Produced during the fermentation of soybeans by the bacterium Bacillus subtilis.[24]
• Serrapeptase (Serratiopeptidase): Originally isolated from the microorganism Serratia marcescens, found in the gut of the silkworm.

Mechanism and Specificity

This is the most critical point of differentiation and has significant implications for both efficacy and safety.

• Lumbrokinase: Exhibits high specificity for fibrin. Its primary actions are the direct degradation of fibrin and the indirect activation of the body's plasminogen system. Its activity is largely confined to the site of a clot, meaning it preserves the integrity of the normal clotting cascade and is less likely to induce systemic hypocoagulability.[12]
• Nattokinase: Possesses broader, less specific activity. While it is an effective fibrinolytic agent, it may also degrade other components of the coagulation system, including thrombin, a key enzyme in clot formation. This broader action means it can disrupt both existing clots and the formation of new, necessary clots, which may raise the potential for excessive bleeding and can affect standard clotting lab tests like PT, PTT, and INR.[24]
• Serrapeptase: Has the lowest specificity of the three. It is a general proteolytic enzyme with relatively mild fibrinolytic activity. Its primary action is non-specific proteolysis, meaning it breaks down a wide range of proteins throughout the body, not just fibrin. It is primarily used for its anti-inflammatory and mucolytic (mucus-thinning) properties.[24]

Safety Implications

The differences in specificity lead to different safety considerations. Due to its highly targeted, fibrin-specific action, lumbrokinase is positioned as a potentially safer option for long-term or sensitive use, particularly in individuals where preserving normal hemostatic function is critical.[24] The broader activity of nattokinase, while effective, carries a higher theoretical risk of interfering with normal coagulation.

Table 2: Comparative Profile of Fibrinolytic Enzymes

Feature	Lumbrokinase	Nattokinase	Serrapeptase
Source	Earthworm (Lumbricus rubellus)	Fermented Soybeans (Bacillus subtilis)	Silkworm (Serratia marcescens)
Primary Mechanism	Direct fibrinolysis & indirect activation of plasminogen	Direct fibrinolysis & potential degradation of thrombin	General proteolysis, mild fibrinolysis
Fibrin Specificity	High. Acts selectively in the presence of fibrin.	Moderate to Low. Broader action, may degrade other clotting factors like thrombin.	Low. Non-specific proteolytic action on a wide range of proteins.
Potency Units	IU, LKU (not standardized)	FU (Fibrinolytic Units), IU	SPU, IU
Key Safety Consideration	Preserves normal clotting cascade; lower theoretical risk of systemic bleeding.	Broader action may increase bleeding risk and affect clotting labs (PT/INR).	Less data on hemostatic effects; primarily used for anti-inflammatory purposes.
Source(s)	24	24	24

7.2. Regulatory Status and Market Positioning

The regulatory status of lumbrokinase is highly fragmented globally, reflecting its dual identity as a traditional medicine, a dietary supplement, and a potential pharmaceutical. This creates a significant global divide in its perception, quality control, and clinical application.

• United States & Canada: In North America, lumbrokinase is marketed and regulated as a dietary supplement.[1] As such, it is not an FDA-approved drug and cannot be legally marketed with claims to diagnose, treat, cure, or prevent any disease.[3] The FDA has issued warning letters to companies marketing similar enzyme products (including nattokinase and serrapeptase) for making such unapproved health claims.[43] A search of the FDA's database of notifications for New Dietary Ingredients (NDIs) does not show a submission for lumbrokinase, indicating it may be marketed based on a history of use prior to 1994 or is in a regulatory gray area.[44] This supplement status leads to significant variability in product quality and potency, with no direct medical oversight for consumers.
• China: In stark contrast, lumbrokinase is recognized by the Ministry of Public Health and is widely used in clinical practice as a prescription or hospital-administered thrombolytic agent. It is integrated into the healthcare system for treating serious conditions like cerebral infarction (ischemic stroke), coronary heart disease, and deep vein thrombosis.[5] In this context, patients receive a product with standardized potency under direct medical supervision.
• Australia: The regulatory status in Australia is not explicitly defined in the provided materials. To be legally supplied, a therapeutic good must be entered on the Australian Register of Therapeutic Goods (ARTG).[45] Lumbrokinase would likely be classified as a complementary medicine, which requires evaluation by the Therapeutic Goods Administration (TGA) for quality and safety, though not necessarily for efficacy unless specific health claims are made.[47] A search of the ARTG would be required to determine if any lumbrokinase-containing products are currently listed for supply.
• Europe: There is no evidence that lumbrokinase has been approved as a medicinal product by the European Medicines Agency (EMA).[48] To be sold as a food supplement, it would likely fall under the Novel Food Regulation (EU) 2015/2283, as earthworm extract does not have a significant history of consumption as a food in the EU before 1997.[52] A search of the EU Novel Food Catalogue reveals no listing for lumbrokinase or earthworm extract, which suggests it has not been authorized for legal sale as a food or food supplement across the European Union.[53]

This regulatory fragmentation is a major obstacle to the global development of lumbrokinase. The divergence in frameworks—from a regulated drug in China to an unregulated supplement in the US—creates profound disparities in product quality, clinical application, and patient safety. A unified, international effort to standardize the product and conduct definitive clinical trials that meet the rigorous standards of multiple global agencies is necessary to bridge this divide and unlock its full therapeutic potential in a safe, effective, and regulated manner.

Section 8: Conclusion and Future Directions

The comprehensive body of evidence reviewed in this report establishes Lumbricus rubellus extract, and its primary bioactive component lumbrokinase, as a therapeutic agent of significant promise. Originating from traditional medicine, it has been subjected to modern scientific scrutiny, revealing a complex and highly favorable pharmacological profile. Its journey from an ancient remedy to a subject of contemporary clinical trials underscores its potential to address critical unmet needs in the management of thrombotic and inflammatory diseases.

8.1. Synthesis of Evidence

The defining characteristic of lumbrokinase is its potent, multi-pronged activity against pathological thrombosis, combined with a remarkable safety profile. Its dual fibrinolytic mechanism—acting both directly on fibrin and indirectly by activating the body's endogenous plasminogen system—allows for effective clot dissolution. This is complemented by significant antithrombotic effects, including the inhibition of platelet aggregation and a reduction in blood viscosity.

The clinical evidence, particularly from a large meta-analysis and several randomized controlled trials in Asia, provides a strong and consistent signal of efficacy for its use as an adjunctive therapy in acute ischemic stroke. These studies demonstrate statistically significant and clinically meaningful improvements in neurological function and daily living activities. Promising pilot data also supports its use in improving myocardial perfusion in patients with stable angina pectoris.

Critically, these benefits are achieved without the high risk of hemorrhage that plagues conventional thrombolytic agents. This unique safety profile is a direct result of its high specificity for fibrin, which allows it to target pathological clots while sparing the components of normal hemostasis. Furthermore, emerging research into its ability to activate the Sirt1 cellular protection pathway suggests its benefits may extend beyond hemostasis to include direct cardioprotective and neuroprotective effects.

8.2. Gaps in Research and Recommendations for Future Studies

Despite its immense potential, several critical gaps in the research and regulatory landscape must be addressed for lumbrokinase to become a globally accepted therapeutic agent. The following recommendations outline a path forward for its future development.

• Urgent Need for Standardization: The single greatest barrier to the clinical advancement of lumbrokinase is the lack of a universal standard for measuring its potency. The use of non-interchangeable units (IU, FU, LKU) creates uncertainty and inconsistency. It is imperative that an international collaborative effort be undertaken to develop and validate a standardized assay and a stable reference standard for lumbrokinase activity. This is the foundational step required to ensure product consistency, enable the replication of clinical findings, and establish clear, evidence-based dosing guidelines.
• Conduct of High-Quality, Global Randomized Controlled Trials: While the existing clinical data is highly encouraging, its widespread acceptance in Western medicine will require validation through large-scale, multi-center, double-blind, placebo-controlled RCTs. Future trials should focus on:
• Confirming Efficacy in Ischemic Stroke: A definitive trial in a diverse, global population is needed to confirm the benefits observed in the Asian studies and meet the rigorous evidentiary standards of the FDA and EMA.
• Expanding Cardiovascular Indications: Rigorous trials are needed to evaluate its efficacy in secondary prevention of myocardial infarction, management of peripheral artery disease, and treatment of deep vein thrombosis.
• Intensive Investigation of Novel Indications: The hypothesis that lumbrokinase can disrupt fibrin/amyloid microclots in post-viral syndromes like Long COVID and ME/CFS is a frontier of immense importance. The ongoing pilot trial (NCT06511050) is a critical first step. Further investment in both basic and clinical research in this area is strongly recommended, as a positive outcome could provide a breakthrough therapy for millions of patients with debilitating chronic illnesses.
• Deeper Mechanistic Elucidation: The discovery of the Sirt1 activation pathway is a significant development. Future preclinical research should aim to fully elucidate the downstream effects of this pathway and determine its clinical relevance across a range of ischemic and inflammatory disease states. Understanding these cellular protection mechanisms could further broaden the therapeutic scope of lumbrokinase.

In conclusion, Lumbricus rubellus extract, powered by the lumbrokinase enzyme complex, stands at a critical juncture. It is a substance with a rich history, compelling scientific rationale, and a strong signal of clinical efficacy and safety. By addressing the current gaps in standardization and clinical evidence through a concerted global research effort, lumbrokinase has the potential to transition from a promising supplement and regional therapeutic into a mainstream, globally recognized medicine for the management of some of the most pressing cardiovascular and chronic diseases of our time.

Works cited

1. Lumbrokinase Earthworm Extract Earthworm Active Protein Powder | Little Ant (Shandong) Bioengineering | Ingredients Network, accessed October 24, 2025, https://www.ingredientsnetwork.com/lumbrokinase-earthworm-extract-earthworm-active-prod1297363.html
2. JEKK KK - Ejournal Undip, accessed October 24, 2025, https://ejournal2.undip.ac.id/index.php/jekk/article/download/9141/11367
3. Boluoke® Lumbrokinase 120 caps - Researched Nutritionals, accessed October 24, 2025, https://www.researchednutritionals.com/product/boluoke-lumbrokinase-120-caps/
4. Lumbrokinase: The Potential Benefits Of An Earthworm Extract - Lam Clinic, accessed October 24, 2025, https://lamclinic.com/blog/lumbrokinase-potential-benefits/
5. Recombinant Protein Production of Earthworm Lumbrokinase for Potential Antithrombotic Application - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3876685/
6. DLBS1033, A Protein Extract from Lumbricus rubellus, Possesses Antithrombotic and Thrombolytic Activities - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3051164/
7. Sirt1 Activation by Post-ischemic Treatment With Lumbrokinase Protects Against Myocardial Ischemia-Reperfusion Injury - Frontiers, accessed October 24, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00636/full
8. What is Lumbrokinase used for? - Patsnap Synapse, accessed October 24, 2025, https://synapse.patsnap.com/article/what-is-lumbrokinase-used-for
9. Lumbrokinase, 60 enteric-coated capsules - Life Extension, accessed October 24, 2025, https://www.lifeextension.com/vitamins-supplements/item25172/lumbrokinase
10. Lumbrokinase – Knowledge and References - Taylor & Francis, accessed October 24, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Lumbrokinase/
11. An Overview of the Fibrinolytic Enzyme from Earth- worm, accessed October 24, 2025, https://resource.iyp.tw/static.iyp.tw/916/files/51badbe435e29.pdf
12. New Enzyme Complex Isolated from Earthworms is Potent Fibrinolytic, accessed October 24, 2025, https://www.acam.org/blogpost/1092863/185721/New-Enzyme-Complex-Isolated-from-Earthworms-is-Potent-Fibrinolytic
13. Antithrombotic Activity of a Lumbrokinase Immobilized Polyurethane Surface - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/8268550/
14. (PDF) A Review: Oral Lumbrokinase as Potential Agent Prevents Myocardial Reinfarction Post-Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/378620860_A_Review_Oral_Lumbrokinase_as_Potential_Agent_Prevents_Myocardial_Reinfarction_Post-Reperfusion_in_ST-Elevation_Myocardial_Infarction_STEMI_Patients
15. DLBS1033, A Protein Extract from Lumbricus rubellus, Possesses Antithrombotic and Thrombolytic Activities - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/50396020_DLBS1033_A_Protein_Extract_from_Lumbricus_rubellus_Possesses_Antithrombotic_and_Thrombolytic_Activities
16. Study Details | NCT01694537 | The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers | ClinicalTrials.gov, accessed October 24, 2025, https://clinicaltrials.gov/study/NCT01694537
17. Antibacterial Activity of Lumbricus Rubellus Earthworm Extract Against Porphyromonas Gingivalis as the Bacterial Cause of Periodontitis - PMC, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6454178/
18. The Efficacy And Benefits of Earthworm Extract as A Herbal Medicine: A Literature Review - International Journal of Research Publications, accessed October 24, 2025, https://ijrp.org/filePermission/fileDownlaod/4/baea6aa7a410b8f87dc5bae940d2ed6e/1
19. Earthworm Extract Lumbricus Rubellus and Pheretima SP Against Salmonella Typhi and Staphylococcus Aureus Bacteria - PSPP Journals, accessed October 24, 2025, https://www.psppjournals.org/index.php/jchp/article/download/109/90
20. Ethanolic extract of the powder of red earthworm (Lumbricus rubellus) obtained from several organic farmlands in Bali, Indonesia: Analysis of total phenolic content and antioxidant capacity - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/319983383_Ethanolic_extract_of_the_powder_of_red_earthworm_Lumbricus_rubellus_obtained_from_several_organic_farmlands_in_Bali_Indonesia_Analysis_of_total_phenolic_content_and_antioxidant_capacity
21. (PDF) Lumbrokinase – A Potent and Stable Fibrin–Specific Plasminogen Activator, accessed October 24, 2025, https://www.researchgate.net/publication/236264109_Lumbrokinase_-_A_Potent_and_Stable_Fibrin-Specific_Plasminogen_Activator
22. Rapid extraction and purification of lumbrokinase from Lumbricus rubellus using a hollow fiber membrane and size exclusion chromatography | Request PDF - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/283050380_Rapid_extraction_and_purification_of_lumbrokinase_from_Lumbricus_rubellus_using_a_hollow_fiber_membrane_and_size_exclusion_chromatography
23. Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy - Frontiers, accessed October 24, 2025, https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.680397/full
24. Earthworms, Enzymes, and Circulation: The Science Behind ..., accessed October 24, 2025, https://www.researchednutritionals.com/lumbrokinase/
25. What is the mechanism of Lumbrokinase? - Patsnap Synapse, accessed October 24, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-lumbrokinase
26. Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8049819/
27. Therapeutic Potential of Lumbrokinase in Acute Ischemic Stroke: A Meta-Analysis of Efficacy and Safety - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12417717/
28. Therapeutic Potential of Lumbrokinase in Acute Ischemic Stroke: A ..., accessed October 24, 2025, https://www.dovepress.com/therapeutic-potential-of-lumbrokinase-in-acute-ischemic-stroke-a-meta--peer-reviewed-fulltext-article-TCRM
29. (PDF) Improved Myocardial Perfusion in Stable Angina Pectoris by ..., accessed October 24, 2025, https://www.researchgate.net/publication/24402264_Improved_Myocardial_Perfusion_in_Stable_Angina_Pectoris_by_Oral_Lumbrokinase_A_Pilot_Study
30. Lumbrokinase Extracted from Earthworms Synergizes with Bevacizumab and Chemotherapeutics in Treating Non-Small Cell Lung Cancer by Targeted Inactivation of BPTF/VEGF and NF-κB/COX-2 Signaling - MDPI, accessed October 24, 2025, https://www.mdpi.com/2218-273X/14/7/741
31. Lumbrokinase, a Fibrinolytic Enzyme, Prevents Intra-Abdominal Adhesion by Inhibiting the Migrative and Adhesive Activities of Fibroblast via Attenuation of the AP-1/ICAM-1 Signaling Pathway - PubMed Central, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9851794/
32. Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/350741206_Effect_of_DLBS1033_on_Functional_Outcomes_for_Patients_with_Acute_Ischemic_Stroke_A_Randomized_Controlled_Trial
33. Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/33927846/
34. A Novel Fibrinolytic Enzyme Extracted from the Earthworm, Lumbricus rubellus, accessed October 24, 2025, https://www.jstage.jst.go.jp/article/jjphysiol/41/3/41_3_461/_article
35. Relationship: Veins and Lumbrokinase - Caring Sunshine, accessed October 24, 2025, https://caringsunshine.com/relationships/relationship-veins-and-lumbrokinase/
36. Effi cacy of Lumbrokinase and Warfarin Compared to Single Warfarin on Thrombus Resolution in Deep Vein Thrombosis | Semantic Scholar, accessed October 24, 2025, https://www.semanticscholar.org/paper/Effi-cacy-of-Lumbrokinase-and-Warfarin-Compared-to-Satuti-Hariawan/c83eea5cc44402ca90c5e3b62245431058bfcb3c
37. Lumbrokinase LongCOVID & ME/CFS clinical trial - PolyBio Research Foundation, accessed October 24, 2025, https://polybio.org/projects/lumbrokinase-longcovid-me-cfs-clinical-trial/
38. Study Details | NCT06511050 | Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | ClinicalTrials.gov, accessed October 24, 2025, https://clinicaltrials.gov/study/NCT06511050
39. Lumbrokinase Supplement - Allergy Research Group, accessed October 24, 2025, https://allergyresearchgroup.com/products/lumbrokinase-delayed-release-vegicaps
40. Lumbrokinase - Researched Nutritionals, accessed October 24, 2025, https://www.researchednutritionals.com/product/lumbrokinase/
41. Lumbrokinase - ITC Compounding Pharmacy, accessed October 24, 2025, https://itcpharmacy.com/product/lumbrokinase/
42. Lumbrokinase Enzymes | Fullscript, accessed October 24, 2025, https://fullscript.com/en-US/catalog/products/enzyme-lumbrokinase?variant=U3ByZWU6OlZhcmlhbnQtMTExMzU0
43. World Nutrition, Inc. - 610003 - 10/27/2020 - FDA, accessed October 24, 2025, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/world-nutrition-inc-610003-10272020
44. Submitted 75-Day Premarket Notifications for New Dietary Ingredients - FDA, accessed October 24, 2025, https://www.fda.gov/media/160660/download
45. Australian Register of Therapeutic Goods (ARTG), accessed October 24, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
46. ARTG Search Visualisation Tool - the Regulatory and Compliance Portal., accessed October 24, 2025, https://compliance.health.gov.au/artg/
47. Inquiry into approval processes for new drugs and novel medical technologies in Australia - Department of Health, Disability and Ageing, accessed October 24, 2025, https://www.health.gov.au/sites/default/files/2023-11/inquiry-into-approval-processes-for-new-drugs-and-novel-medical-technologies-in-australia.pdf
48. EMA backs restrictions on certain immune-regulating drugs - BioPharma Dive, accessed October 24, 2025, https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/
49. Procedures for nationally authorised products for human use - Union Register of medicinal products - Public health - European Commission, accessed October 24, 2025, https://ec.europa.eu/health/documents/community-register/html/ho26829.htm
50. EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines - PharmaNews.eu, accessed October 24, 2025, https://www.pharmanews.eu/ema/2856-ema-confirms-recommendation-to-withdraw-marketing-authorisations-for-amfepramone-medicines
51. EMA recommended 77 drugs, rejected 3 in 2023 - RAPS, accessed October 24, 2025, https://www.raps.org/news-and-articles/news-articles/2024/1/ema-approved-77-drugs,-rejected-3-in-2023
52. Application of 'novel food' regulation regarding insects for human consumption in Belgium -------------------, accessed October 24, 2025, https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/2023_11_20_qna_novel_foods_insects_final_en.pdf
53. Novel Food status Catalogue - Food Safety - European Commission, accessed October 24, 2025, https://food.ec.europa.eu/food-safety/novel-food/novel-food-status-catalogue_en
54. Search Novel Food status Catalogue | Food and Feed Information Portal Database | FIP, accessed October 24, 2025, https://ec.europa.eu/food/food-feed-portal/screen/novel-food-catalogue/search